HALO - HALOZYME THERAPEUTICS, INC.

QQQ $ 604.48 $ -3.85 (-0.63 %)

DIA $ 467.21 $ -1.00 (-0.21 %)

SPY $ 665.98 $ -2.00 (-0.3 %)

TLT $ 89.76 $ 0.39 (0.44 %)

GLD $ 368.52 $ 0.53 (0.14 %)

Previous Close

$ 68.39

Open

$ 68.91

Bid

$ 68.60 x 58

Ask

$ 68.81 x 25

Day's Range

$ 67.73 - $ 69.87

52 Week Range

$ 42.01 - $ 79.50

Volume

2,328,609

Average Volume

Market Cap

8.04B

Beta (5Y Monthly)

$ 0.91

PE Ratio (TTM)

$ 13.51

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-03-2025	09-30-2025	10-Q
2	08-05-2025	06-30-2025	10-Q
3	05-06-2025	03-31-2025	10-Q
4	02-18-2025	12-31-2024	10-K
5	10-31-2024	09-30-2024	10-Q
6	08-06-2024	06-30-2024	10-Q
7	05-07-2024	03-31-2024	10-Q
8	02-20-2024	12-31-2023	10-K
9	11-06-2023	09-30-2023	10-Q
10	08-08-2023	06-30-2023	10-Q
11	05-09-2023	03-31-2023	10-Q
12	02-21-2023	12-31-2022	10-K
13	11-08-2022	09-30-2022	10-Q
14	08-09-2022	06-30-2022	10-Q
15	05-10-2022	03-31-2022	10-Q
16	02-22-2022	12-31-2021	10-K
17	11-02-2021	09-30-2021	10-Q
18	08-09-2021	06-30-2021	10-Q
19	05-10-2021	03-31-2021	10-Q
20	02-23-2021	12-31-2020	10-K
21	11-02-2020	09-30-2020	10-Q
22	08-10-2020	06-30-2020	10-Q
23	05-11-2020	03-31-2020	10-Q
24	02-24-2020	12-31-2019	10-K
25	11-12-2019	09-30-2019	10-Q
26	08-06-2019	06-30-2019	10-Q
27	05-07-2019	03-31-2019	10-Q
28	02-21-2019	12-31-2018	10-K
29	11-06-2018	09-30-2018	10-Q
30	08-07-2018	06-30-2018	10-Q
31	05-10-2018	03-31-2018	10-Q
32	02-20-2018	12-31-2017	10-K
33	11-07-2017	09-30-2017	10-Q
34	08-08-2017	06-30-2017	10-Q
35	05-09-2017	03-31-2017	10-Q
36	02-28-2017	12-31-2016	10-K
37	11-07-2016	09-30-2016	10-Q
38	08-09-2016	06-30-2016	10-Q
39	05-09-2016	03-31-2016	10-Q
40	02-29-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Halozyme Therapeutics Announces Johnson & ...
11/07/2025 13:31:58

Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Adm...

Reported Earlier, Halozyme Therapeutics Pr...
11/07/2025 08:02:02

Halozyme Therapeutics Announces Proposed $...
11/05/2025 21:50:10

Halozyme Therapeutics Raises FY2025 Adj EP...
11/03/2025 21:03:19

Halozyme Therapeutics Q3 Adj. EPS $1.72 Be...
11/03/2025 21:02:27

Earnings Scheduled For November 3, 2025
11/03/2025 11:11:31

Insights into Halozyme Therapeutics's Upco...
10/31/2025 18:02:23

JP Morgan Maintains Neutral on Halozyme Th...
10/27/2025 14:19:59

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from ...

Morgan Stanley Maintains Overweight on Hal...
10/20/2025 15:35:18

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and lowers the price t...

The Analyst Verdict: Halozyme Therapeutics...
10/15/2025 20:01:22

HC Wainwright & Co. Reiterates Buy on Halo...
10/15/2025 10:31:43

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $...

Leerink Partners Upgrades Halozyme Therape...
10/14/2025 18:22:24

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Underperform to Market Perform and...

HC Wainwright & Co. Maintains Buy on Haloz...
10/02/2025 10:33:51

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the p...

Halozyme To Acquire Elektrofi In Deal Comp...
10/01/2025 11:05:20

Benchmark Maintains Buy on Halozyme Therap...
09/24/2025 12:24:30

Benchmark analyst Robert Wasserman maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from...

Forecasting The Future: 7 Analyst Projecti...
09/22/2025 12:02:57

HC Wainwright & Co. Maintains Buy on Haloz...
09/22/2025 10:36:37

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the p...

What 7 Analyst Ratings Have To Say About H...
08/18/2025 20:01:43

Morgan Stanley Maintains Overweight on Hal...
08/18/2025 12:52:31

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price t...

JP Morgan Maintains Neutral on Halozyme Th...
08/07/2025 19:17:29

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from ...